fbpx

News

Lundbeckfonden Emerge News

SAN DIEGO and COPENHAGEN, Denmark, Nov. 18, 2020 /PRNewswire/ — AFYX Therapeutics (“AFYX”), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced the appointment of Dennis D. Kim, M.D., MBA, as chief medical officer. Dr. Kim will lead the clinical development of Rivelin®-Clobetesol for the treatment of oral lichen planus, Rivelin®-Mometasone for...
Copenhagen, Oct. 2020   SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, today announced the appointment of Dr. Milan Zdravkovic, MD, PhD as Chief Medical Officer from 01 November 2020. Dr. Zdravkovic will lead SNIPR Biome’s development activities.   Before joining SNIPR Biome, Dr. Zdravkovic was most recently Chief Medical Officer and Head...
Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that the first subject has been dosed in a Phase I/IIa clinical trial of NMD670, NMD Pharma’s lead program in development to treat the symptoms of myasthenia gravis (MG). The trial...
– Data to be Presented at the ESMO Virtual Congress 2020 – Melanoma trial (MM1636) shows best-in-class efficacy data in first line melanoma of IO102 and IO103 in combination with nivolumab (anti-PD1 antibody) Copenhagen, Denmark – September 18, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology,...
Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that it has received approval from the Dutch ethics committee and regulatory authorities to advance its development candidate, NMD670, into clinical trials as a novel treatment for the symptoms of myasthenia...
SAN DIEGO and COPENHAGEN, April 22, 2020 /PRNewswire/ — AFYX Therapeutics (“AFYX”), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that its Rivelin® Clobetasol patch (“Rivelin-CLO”) met the primary and multiple secondary endpoints in a Phase 2b study in patients with oral lichen planus (“OLP”). In the largest randomized, double-blind, placebo-controlled...
Data position the company to start potential registrational trials with two drugs in two tumor types Copenhagen, Denmark – February 25, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing Phase 2 trial (IO102-012/KEYNOTE-764) of...
SAN DIEGO and COPENHAGEN, Denmark, Oct. 9, 2019 /PRNewswire/ — AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced results from a Phase 1 clinical proof of concept study evaluating the use of the Rivelin® bio-adhesive patch in patients with vulvar lichen sclerosus (VLS), a painful genital skin condition that affects up to 3% of post-menopausal women....
In April, US investors have the opportunity to meet with 23 Danish biotech startups in New York during DKBIO 2019. Denmark already today has a thriving biotech and pharma industry fuelled by a strong academic environment, talent pool and capital. DKBIO conference on 10 and 11 April in New York provides a platform for US...
1 2 3

Lundbeckfonden Emerge

News

AFYX Therapeutics Appoints Dennis Kim, M.D., MBA, as Chief Medical Officer
18. November 2020
SNIPR BIOME appoints Dr Milan Zdravkovic as Chief Medical Officer
19. October 2020
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
8. October 2020